Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...
Zacks.com on MSN7h
Can Gilead Sciences Sustain Its Growth Momentum in 2025?Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback